M A Fletcher

Summary

Affiliation: Wyeth Research
Country: USA

Publications

  1. ncbi Time to recommend pneumococcal vaccination for all children in Europe: experience in France
    Mark A Fletcher
    International Scientific Affairs, Wyeth Vaccines Research, Puteaux Paris La Défense, France
    Eur J Pediatr 161:S132-4. 2002
  2. ncbi Vaccine candidates in STD
    Mark A Fletcher
    Medical Affairs Department, Aventis Pasteur, 2, avenue Pont Pasteur, F 69367 Lyon Cedex 07, France
    Int J STD AIDS 13:38-41. 2002
  3. ncbi Vaccines administered simultaneously: directions for new combination vaccines based on an historical review of the literature
    Mark A Fletcher
    Wyeth Vaccines Research, Coeur Défense Tour A, 110 esplanade du Général de Gaulle, 92931 Paris la Défense, Cedex, France
    Int J Infect Dis 8:328-38. 2004
  4. ncbi Brief review of the clinical effectiveness of PREVENAR against otitis media
    Mark A Fletcher
    International Scientific and Clinical Affairs, Wyeth Vaccines Research, Coeur Défense Tour A, 05TA077, La Défense 4, 110 esplanade du Général de Gaulle, 92931 Paris La Défense Cedex, France
    Vaccine 25:2507-12. 2007
  5. ncbi Controlling invasive pneumococcal disease: is vaccination of at-risk groups sufficient?
    M A Fletcher
    Wyeth Vaccines Research, Paris, France
    Int J Clin Pract 60:450-6. 2006
  6. ncbi Vaccine candidates in STD
    M A Fletcher
    Medical Affairs Department, Aventis Pasteur, 2 avenue Pont Pasteur, F-69367 Lyon Cedex 07, France
    Int J STD AIDS 12:419-22. 2001
  7. ncbi Burden of paediatric invasive pneumococcal disease in Europe, 2005
    E D G McIntosh
    Global Medical Affairs, Wyeth Europa, Vanwall Road, Maidenhead, Berks SL6 4UB, UK
    Epidemiol Infect 135:644-56. 2007
  8. ncbi Haemophilus influenzae type b vaccine: reconstitution of lyophilised PRP-T vaccine with a pertussis-containing paediatric combination vaccine, or a change in the primary series immunisation schedule, may modify the serum anti-PRP antibody responses
    E Vidor
    Clinical Development Department, Aventis Pasteur, Lyon, France
    Curr Med Res Opin 17:197-209. 2001
  9. ncbi The efficacy of whole cell pertussis immunisation: collected data on a vaccine produced in France
    M A Fletcher
    Medical Affairs, Aventis Pasteur SA, 2 avenue Pont Pasteur, F 69367 Lyon Cedex 07, France
    Public Health 115:119-29. 2001
  10. ncbi Evaluation of the safety and immunogenicity of pneumococcal seven-valent conjugate vaccine (Prevenar) administered in previously unvaccinated Spanish children aged 24 to 36 months
    Javier de Arístegui Fernández
    Pediatric Department, Basurto Hospital, Bilbao, Spain
    Vaccine 23:1917-22. 2005

Collaborators

Detail Information

Publications11

  1. ncbi Time to recommend pneumococcal vaccination for all children in Europe: experience in France
    Mark A Fletcher
    International Scientific Affairs, Wyeth Vaccines Research, Puteaux Paris La Défense, France
    Eur J Pediatr 161:S132-4. 2002
    ..CONCLUSION: in this way, the Direction Générale de la Santé and Wyeth are working towards the implementation of a broad-scale vaccine introduction...
  2. ncbi Vaccine candidates in STD
    Mark A Fletcher
    Medical Affairs Department, Aventis Pasteur, 2, avenue Pont Pasteur, F 69367 Lyon Cedex 07, France
    Int J STD AIDS 13:38-41. 2002
    ....
  3. ncbi Vaccines administered simultaneously: directions for new combination vaccines based on an historical review of the literature
    Mark A Fletcher
    Wyeth Vaccines Research, Coeur Défense Tour A, 110 esplanade du Général de Gaulle, 92931 Paris la Défense, Cedex, France
    Int J Infect Dis 8:328-38. 2004
    ..If contemporary research and development can realize vaccines that achieve the current standards for safety, immunogenicity, and efficacy, other specific vaccine associations may also merit reconsideration as combination vaccines...
  4. ncbi Brief review of the clinical effectiveness of PREVENAR against otitis media
    Mark A Fletcher
    International Scientific and Clinical Affairs, Wyeth Vaccines Research, Coeur Défense Tour A, 05TA077, La Défense 4, 110 esplanade du Général de Gaulle, 92931 Paris La Défense Cedex, France
    Vaccine 25:2507-12. 2007
    ..Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J 2004;23(9):829-33 [see comment]]...
  5. ncbi Controlling invasive pneumococcal disease: is vaccination of at-risk groups sufficient?
    M A Fletcher
    Wyeth Vaccines Research, Paris, France
    Int J Clin Pract 60:450-6. 2006
    ....
  6. ncbi Vaccine candidates in STD
    M A Fletcher
    Medical Affairs Department, Aventis Pasteur, 2 avenue Pont Pasteur, F-69367 Lyon Cedex 07, France
    Int J STD AIDS 12:419-22. 2001
    ....
  7. ncbi Burden of paediatric invasive pneumococcal disease in Europe, 2005
    E D G McIntosh
    Global Medical Affairs, Wyeth Europa, Vanwall Road, Maidenhead, Berks SL6 4UB, UK
    Epidemiol Infect 135:644-56. 2007
    ..Because of the excellent clinical efficacy of the PCV against IPD, national pneumococcal vaccination programmes in Europe have the potential to prevent much morbidity and mortality...
  8. ncbi Haemophilus influenzae type b vaccine: reconstitution of lyophilised PRP-T vaccine with a pertussis-containing paediatric combination vaccine, or a change in the primary series immunisation schedule, may modify the serum anti-PRP antibody responses
    E Vidor
    Clinical Development Department, Aventis Pasteur, Lyon, France
    Curr Med Res Opin 17:197-209. 2001
    ....
  9. ncbi The efficacy of whole cell pertussis immunisation: collected data on a vaccine produced in France
    M A Fletcher
    Medical Affairs, Aventis Pasteur SA, 2 avenue Pont Pasteur, F 69367 Lyon Cedex 07, France
    Public Health 115:119-29. 2001
    ....
  10. ncbi Evaluation of the safety and immunogenicity of pneumococcal seven-valent conjugate vaccine (Prevenar) administered in previously unvaccinated Spanish children aged 24 to 36 months
    Javier de Arístegui Fernández
    Pediatric Department, Basurto Hospital, Bilbao, Spain
    Vaccine 23:1917-22. 2005
    ..50 microg/mL for all serotypes. CONCLUSIONS: Pneumococcal seven-valent conjugate vaccine (Prevenar) was safe, well tolerated and highly immunogenic when administered in previously unvaccinated children aged 14-36 months...
  11. ncbi Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar)
    Daniel J Isaacman
    Global Medical Affairs, Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, PA 19426, USA
    Vaccine 25:2420-7. 2007
    ..Continued surveillance will be important, to follow future changes associated with non-vaccine type IPD, particularly among individuals with medical co-morbidities that may put them at higher risk of disease...